Latest

16:57
【Tianjin Tianbao Energy Co., Ltd. (01671.HK): Awarded AAA-level Top Credit Rating in Tianjin's Power Sales Industry, with Comprehensive Strength Recognized by Authorities】Tianjin Tianbao Energy Co., Ltd. announced that in December 2025, it was rated as the AAA-level top credit grade in the power sales industry by Tianjin Electric Power Trading Center, becoming one of the 13 power sales companies in Tianjin to receive this rating. Conducted through a comprehensive assessment across multiple dimensions including financial status and compliance management, this rating signifies that the company's core capabilities such as market-oriented transaction and risk control have gained high recognition from the industry.
Tag： Tianjin Tianbao Energy Co., Ltd.01671.HKCredit Rating
16:47
【Sunac China Completes Offshore Debt Restructuring, Winding-Up Petition Dismissed by Court】Sunac China Holdings Limited (01918.HK) announced that, following the completion of its comprehensive offshore debt restructuring on December 23, 2025, the Hong Kong High Court issued an order on January 5, 2026 to dismiss the winding-up petition. The petition was jointly applied for withdrawal by the company and the petitioner, China Cinda (HK) Asset Management Company Limited. Currently, the company has no outstanding winding-up petitions.
Tag： Sunac China01918.HKdebt restructuring
07:50
【SKB BIO-B(06990.HK): TROP2 ADC Combined with Immunotherapy Gets Breakthrough Designation, Accumulating Five Relevant Qualifications】On January 5, 2026, SKB BIO-B(06990.HK) issued an announcement stating that its core product sacituzumab govitecan (SAC-TMT) in combination with pembrolizumab for the first-line treatment of specific PD-L1-positive locally advanced or metastatic non-small cell lung cancer has been granted Breakthrough Therapy Designation by the NMPA. This designation supports subsequent conditional approval and priority review applications to accelerate the launch of the indication. Previous relevant Phase 3 clinical trials have shown significant clinical benefits, and the product has accumulated five Breakthrough Therapy Designations, with three indications approved in China and two included in medical insurance. The company and MSD are also advancing multiple clinical studies globally, while the announcement reminds that the development and commercialization of unapproved indications are subject to uncertainties.
Tag： SKB BIO-B06990.HKinnovative drug
22:00
【Zhongzheng International Company Limited (00943.HK): Acquires beauty industry digital service provider for HK$62.5 million, resumption of trading on January 5】Zhongzheng International entered into an acquisition agreement with the seller, proposing to acquire all equity interests in the target company (a digital service provider in the beauty industry) and the outstanding shareholder loans for HK$62.5 million. The consideration will be settled by issuing 342 million consideration shares at HK$0.1828 per share.
Tag： Zhongzheng International00943.HKacquire
21:55
【Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.(01349.HK): Invests RMB210 million in SPD Bank structured deposits to enhance idle fund returns】Fudan Zhangjiang entered into an agreement with SPD Bank to subscribe to a structured deposit product with RMB210 million of its own idle funds generated from daily operations. The product is a principal-guaranteed floating-income type with a term of 87 days, an expected annualized return rate ranging from 0.70% to 1.90%, and is linked to the euro-to-U.S. dollar exchange rate.
Tag： Fudan Zhangjiang01349.HKsubscribe
18:18
【S.F. Holding Co., Ltd.(06936.HK): Repurchases A-shares for over RMB1.5 billion at an average price of RMB39.59/share, demonstrating confidence in value】S.F. Holding announced that as of December 31, 2025, it had repurchased a total of nearly 39 million A-shares with an aggregate amount of approximately RMB1.542 billion, representing 102.8% of the minimum target (RMB1.5 billion) under the share repurchase program, at an average transaction price of RMB39.59 per share.
Tag： S.F. Holding Co., Ltd06936.HKShare Repurchase
09:28
【EVE Energy Co., Ltd. (300014.SZ)：Submits Listing Application to HKEX, Ranking Second Globally in Energy Storage Battery Shipments】EVE Energy Co., Ltd. (300014.SZ) formally submitted an application for a main board listing on the Hong Kong Stock Exchange on January 2, with CITIC Securities acting as the sole sponsor. The company is one of the few globally integrated lithium battery platform enterprises covering consumer, power, and energy storage batteries across all application scenarios. In 2024, it ranked second globally in energy storage battery shipments, while also maintaining leading positions in the consumer and power battery sectors.
Tag： EVE Energy300014.SZIPONewTimeSpace
16:41
【Backed by HKIC and Semiconductor Gurus Li Zexiang & Gao Bingqiang, OneRobotics Lists on HKEX as the First AI Embodied Home Robot Stock】OneRobotics (stock code: 06600.HK) was listed on the Hong Kong Exchanges and Clearing Limited (HKEX) on December 30. On the following day, its shares closed 9.21% higher at HK$80.65, with a market capitalization of nearly HK$18 billion, earning it the title of "the first AI Embodied Home Robot Stock". Founded in Shenzhen in 2015, the company is headquartered in the city and houses its global sales and intelligent computing hubs in Hong Kong, focusing on the R&D of AI home robots. It has secured strategic investment from the Hong Kong Investment Corporation Limited (HKIC) as well as early backing from renowned semiconductor experts Li Zexiang and Gao Bingqiang.
16:39
【New IPO Watch | On the Crest of the LLM Wave: As the “Top Player” Knowledge Atlas Launches HK IPO, What Future is the Market Betting On?】On December 30, 2025, Knowledge Atlas (02513.HK) officially launched its public offering, which will close on January 5, 2026, with an expected listing date of January 8, 2026. The offer price has been set at HK$116.20 per share, with a board lot of 100 shares, an entry cost of approximately HK$11,737.19, and a total fundraising amount of about HK$4.17 billion. Newtimespace observes that as one of the few domestic companies with full-stack, self-developed capabilities in large models, Knowledge Atlas is at the forefront in terms of technical prowess, open-source ecosystem, and commercialization efforts. However, it faces risks such as intense market competition and inclusion on the U.S. "Entity List," making its post-listing growth trajectory a key focus for market attention.
Tag： Knowledge Atlas02513.HKIPONewTimeSpace
12:05
【Insilico Medicine Launches Hong Kong's Largest Biopharma IPO of the Year with HKIC as Strategic Investor】On December 30, 2025, Insilico Medicine, hailed as "the first AI-driven pharmaceutical stock on the Hong Kong stock market" and a strategic investment of the Hong Kong Investment Corporation Limited (HKIC), was listed on the Main Board of the Hong Kong Exchanges and Clearing Limited (HKEX). With a total fundraising of HK$2.277 billion, it has claimed the title of the largest IPO in the biopharmaceutical sector of the Hong Kong stock market in 2025, and its share price delivered an impressive performance on the debut day. It is reported that Biren Technology, another portfolio company of HKIC, is also set to list on the HKEX on January 2, 2026, which indicates that the effectiveness of HKIC’s diversified strategic investment layout continues to unfold.
Tag： InsilicoHKICIPObiopharmaceutical
17:26
【NewTimeSpace English Version Officially Launched】On December 30,2025,NewTimeSpace,an AI-powered international financial media outlet,launched its English version.It provides bilingual (Chinese and English) financial information, covering niche areas such as IPOs and ETFs, and connects Chinese enterprises with global capital.
Tag： NewTimeSpaceNewTimeSpace MediaEnglish version
17:00
【Knowledge Atlas(02513.HK): Launches IPO on December 30, proposing to globally offer 37.4195 million H shares】Knowledge Atlas(02513.HK) announced that it will conduct an IPO from December 30, 2025 to January 5, 2026, planning to globally offer 37.4195 million H shares, with an offer price of HK$116.20 per share. The H shares are expected to start trading on the Hong Kong Stock Exchange at 9:00 a.m. on January 8, 2026.
Tag： Knowledge Atlas02513.HKIPOIPO Offering
17:00
【NewTimeSpace Hong Kong Stock Market Close | Three Major Indices Fluctuate and Strengthen, Hang Seng Index Closes Up 0.86%, Robotics, Semiconductors and Other Sectors Lead Gains】On December 30, 2025, Hong Kong's three major indices fluctuated and strengthened. The Hang Seng Index closed up 0.86%, the Hang Seng Tech Index rose 1.74%, and the Hang Seng China Enterprises Index climbed 1.12%. The total market trading volume reached HK$199.769 billion, with a net outflow of HK$3.845 billion in Southbound Capital.
Tag： Hang Seng IndexNewTimeSpace
Previous1..233234235236 237     237 pages total
×
Share to WeChat

Open WeChat, use "Scan," and share to my Moments